# cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells

**Authors:** Yan Ouyang, Yilin Qin, Qianmin Zhang, Pengcheng Zhu, Huifang Zhu

PMC · DOI: 10.3389/fonc.2026.1764427 · Frontiers in Oncology · 2026-02-23

## TL;DR

This study shows that DNA damage in leukemia stem cells activates a pathway that increases NK cell sensitivity, helping the immune system fight cancer.

## Contribution

The novel finding is that the cGAS/STING pathway mediates NKG2D ligand upregulation in leukemia stem cells after DNA damage.

## Key findings

- PARP1 inhibition in LSCs activates DNA damage response and increases NKG2D ligand expression.
- The cGAS/STING/TBK1/IRF3 pathway is essential for NKG2D ligand upregulation in LSCs.
- STING and IRF3 knockdown reduces NKG2D ligand expression, confirming their role in DNA damage response.

## Abstract

Natural killer (NK) cells-mediated immune surveillance is essential role for tumor recognition and elimination. The binding of NK group 2 member D (NKG2D) ligands to NKG2D receptor is sufficient to activate the NK cells' cytotoxicity against targeted cells. Here we reported that the inhibition of poly (ADP-ribose) polymerase 1 (PARP1) in leukemia stem cells (LSCs) induced the expression of NKG2D ligands through the activation of DNA damage response.

Flow cytometry and Quantitative real-time RT-PCR were used to detect the expression levels of NKG2D ligands on cell surface and mRNA levels in leukemia cells, respectively. Cytotoxicity assay was applied to examine the cytotoxic activity of NK cells against leukemia cells. Dual luciferase reporter (DLR) assay was employed to detect the promoter activation of NKG2D ligands. Western blotting was conducted to check the protein expression level.

Activated ataxia-telangiectasia mutated proteins (ATM) and ɣH2AX foci accumulation were observed under the treatment of PARP inhibitor, leading to the accumulation of damaged DNA. Subsequently, cyclic GMP-AMP synthase (cGAS) was activated, and stimulator of interferon gene (STING) was recruited to promote the downstream signal transduction via TANK-binding kinase-1 (TBK1) and transcription regulatory factor 3 (IRF3). However, the NKG2D ligands induced by PARP inhibitor was reduced in STING or IRF3-knockdown LSCs, indicating that STING and IRF3 were necessary for the regulation of NGK2D ligands in LSCs upon the DNA damage response.

These data indicated that the DNA damage response-mediated cGAS/STING/TBK1/IRF3 signalling pathway played an essential role in modulating NKG2D ligands expression in LSCs.

## Linked entities

- **Genes:** PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142], ATM (ATM serine/threonine kinase) [NCBI Gene 472], STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061], TBK1 (TANK binding kinase 1) [NCBI Gene 29110], IRF3 (interferon regulatory factor 3) [NCBI Gene 3661], KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914]
- **Proteins:** PARP1 (poly(ADP-ribose) polymerase 1), ATM (ATM serine/threonine kinase), CGAS (cyclic GMP-AMP synthase), STING1 (stimulator of interferon response cGAMP interactor 1), TBK1 (TANK binding kinase 1), IRF3 (interferon regulatory factor 3)
- **Diseases:** leukemia (MONDO:0004355)

## Full-text entities

- **Genes:** CAT (catalase) [NCBI Gene 847], RAE1 (ribonucleic acid export 1) [NCBI Gene 8480] {aka Gle2, MIG14, MRNP41, Mnrp41, dJ481F12.3, dJ800J21.1}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}, PRAP1 (proline rich acidic protein 1) [NCBI Gene 118471] {aka PRO1195, UPA}, PARP11 (poly(ADP-ribose) polymerase family member 11) [NCBI Gene 57097] {aka ARTD11, C12orf6, MIB006}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, Klrk1 (killer cell lectin-like receptor subfamily K, member 1) [NCBI Gene 27007] {aka D6H12S2489E, NKG2-D, Nkg2d}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, IL3 (interleukin 3) [NCBI Gene 3562] {aka IL-3, MCGF, MULTI-CSF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, Rae1 (ribonucleic acid export 1) [NCBI Gene 66679] {aka 3230401I12Rik, D2Ertd342e, MNRP, MNRP41}, TUBA1B (tubulin alpha 1b) [NCBI Gene 10376] {aka K-ALPHA-1}, H2ax (H2A.X variant histone) [NCBI Gene 15270] {aka H2A.X, H2afx, Hist5-2ax, gammaH2ax}, FLT3LG (fms related receptor tyrosine kinase 3 ligand) [NCBI Gene 2323] {aka FL, FLG3L, FLT3L, IMD125}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, ULBP2 (UL16 binding protein 2) [NCBI Gene 80328] {aka ALCAN-alpha, N2DL2, NKG2DL2, RAET1H}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, PARP12 (poly(ADP-ribose) polymerase family member 12) [NCBI Gene 64761] {aka ARTD12, MST109, MSTP109, ZC3H1, ZC3HDC1}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, Atm (ataxia telangiectasia mutated) [NCBI Gene 11920] {aka C030026E19Rik}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, MICA (MHC class I polypeptide-related sequence A) [NCBI Gene 100507436] {aka MIC-A, PERB11.1}, ULBP3 (UL16 binding protein 3) [NCBI Gene 79465] {aka N2DL-3, NKG2DL3, RAET1N}, TBK1 (TANK binding kinase 1) [NCBI Gene 29110] {aka AIARV, FTDALS4, IIAE8, NAK, T2K}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, Parp1 (poly (ADP-ribose) polymerase family, member 1) [NCBI Gene 11545] {aka 5830444G22Rik, ARTD1, Adprp, Adprt1, PARP, PPOL}, Ulbp1 (UL16 binding protein 1) [NCBI Gene 77777] {aka A430108B07Rik, MULT1}, Atr (ataxia telangiectasia and Rad3 related) [NCBI Gene 245000], ULBP1 (UL16 binding protein 1) [NCBI Gene 80329] {aka N2DL-1, NKG2DL1, RAET1I}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, CD34 (CD34 molecule) [NCBI Gene 947], KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, MICB (MHC class I polypeptide-related sequence B) [NCBI Gene 4277] {aka PERB11.2}, Prap1 (proline-rich acidic protein 1) [NCBI Gene 22264] {aka Upa}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TPO (thyroid peroxidase) [NCBI Gene 7173] {aka MSA, TDH2A, TPX}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}
- **Diseases:** Cytotoxicity (MESH:D064420), metastasis (MESH:D009362), leukemia (MESH:D007938), death (MESH:D003643), breast cancer (MESH:D001943), lymphoma (MESH:D008223), LSCs (MESH:D015458), bone marrow tumor (MESH:D019046), cancer (MESH:D009369), hematologic malignancies (MESH:D019337), AML (MESH:D015470), tumorigenesis (MESH:D063646), Hodgkin lymphoma (MESH:D006689)
- **Chemicals:** Fluorescein (MESH:D019793), HY-15520 (-), penicillin (MESH:D010406), CGK733 (MESH:C512273), PBS (MESH:D007854), Talazoparib (MESH:C586365), DAPI (MESH:C007293), DMSO (MESH:D004121), CO2 (MESH:D002245), L-Glutamine (MESH:D005973), Olaparib (MESH:C531550), Niraparib (MESH:C545685), paraformaldehyde (MESH:C003043), FITC (MESH:D016650), streptomycin (MESH:D013307), Ficoll (MESH:D005362), SDS (MESH:D012967)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** KG-1alpha — Homo sapiens (Human), Acute myeloid leukemia without maturation, Cancer cell line (CVCL_1824), NK92 MI — Homo sapiens (Human), Natural killer cell lymphoblastic leukemia/lymphoma, Cancer cell line (CVCL_3755), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), HL60 — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_0002), NK92 — Homo sapiens (Human), Natural killer cell lymphoblastic leukemia/lymphoma, Cancer cell line (CVCL_2142), pLKO.1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), Kasumi-1 — Homo sapiens (Human), Childhood acute myeloid leukemia with maturation, Cancer cell line (CVCL_0589)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967932/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967932/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967932/full.md

---
Source: https://tomesphere.com/paper/PMC12967932